CZACHOR, Adrianna, SERVAAS, Elwira, KOTULA, Alicja, HABER, Mateusz, GRELEWICZ, Olga, KUCY, Natalia, JUŚKIEWICZ, Adam and KULA, Paula. Cardiovascular Risks of Methylphenidate in Children with ADHD. Journal of Education, Health and Sport. 2024;65:55139. eISSN 2391-8306.
https://dx.doi.org/10.12775/JEHS.2024.65.55139
https://apcz.umk.pl/JEHS/article/view/55139

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 13.09.2024. Revised: 15.09.2024. Accepted: 07.10.2024. Published: 08.10.2024.

Cardiovascular Risks of Methylphenidate in Children with ADHD

Adrianna Czachor
Infant Jesus Clinical Hospital UCC MUW
Lindleya 4, 02-005 Warszawa
adriannaczachor@gmail.com
https://orcid.org/0009-0001-8596-9341

Elwira Servaas
National Medical Institute of the Ministry of the Interior and Administration
Wołoska 137, 02-507 Warszawa
servaaselwira@gmail.com
https://orcid.org/0009-0004-8432-7824

Alicja Kotula
Infant Jesus Clinical Hospital UCC MUW
Lindleya 4, 02-005 Warszawa
kotulaalicja5@gmail.com
https://orcid.org/0009-0008-9718-1667

Mateusz Haber
Central Clinical Hospital in Warsaw
Banacha 1a, 02-097, Warszawa
mhaber.mateusz@gmail.com
https://orcid.org/0009-0002-8441-4931

Olga Grelewicz
National Medical Institute of the Ministry of the Interior and Administration
Wołoska 137, 02-507 Warszawa
olga.grelewicz@gmail.com
https://orcid.org/0000-0001-5738-9262

Natalia Kucy
Infant Jesus Clinical Hospital UCC MUW
Lindleya 4, 02-005 Warszawa
tusia.noelle@icloud.com
https://orcid.org/0009-0007-5468-6289

Adam Juśkiewicz
National Medical Institute of the Ministry of the Interior and Administration
Wołoska 137, 02-507 Warszawa
ad.juskiewicz@gmail.com
https://orcid.org/0000-0001-9884-3513

Paula Kula
Central Clinical Hospital in Warsaw,
Banacha 1a, 02-097, Warszawa
paulakula98@gmail.com
https://orcid.org/0009-0004-7503-2602

ABSTRACT

Introduction: Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder affecting millions of children worldwide. Methylphenidate is one of the most prescribed medications for managing ADHD symptoms due to its proven efficacy. However, despite its widespread use and effectiveness, there are ongoing concerns about the cardiovascular safety of methylphenidate, particularly in pediatric populations. These concerns stem from reports of increased heart rate, elevated blood pressure, and, in rare cases, more severe cardiovascular events.

Aim of the Study: To review recent studies on the cardiovascular safety of methylphenidate in children with ADHD, synthesizing findings to inform clinical practice.

Materials and Methods: A comprehensive literature review was conducted, focusing on studies published in the last decade that investigated the cardiovascular effects of methylphenidate in children with ADHD.

Conclusion: The review highlights that while methylphenidate is generally well-tolerated, there are notable cardiovascular risks, particularly in susceptible children. These risks underscore the importance of thorough cardiovascular assessment and monitoring in children undergoing treatment with methylphenidate. The findings advocate for a balanced approach where the benefits of symptom management are weighed against potential cardiovascular risks. Clinicians are advised to adopt comprehensive monitoring strategies and consider individual risk factors when prescribing methylphenidate to children with ADHD.

Keywords: ADHD, methylphenidate, cardiovascular safety, children, treatment, monitoring.

INTRODUCTION

Attention Deficit Hyperactivity Disorder (ADHD) is a chronic condition that affects approximately 5-10% of children globally. Characterized by persistent patterns of inattention, hyperactivity, and impulsivity, ADHD can lead to significant functional impairments in various aspects of life, including academic performance, social interactions, and family dynamics. The etiology of ADHD is multifactorial, involving genetic, environmental, and neurological factors. [7, 25]

Methylphenidate, a central nervous system stimulant, is commonly prescribed for the treatment of ADHD. It functions primarily by inhibiting the reuptake of dopamine and norepinephrine into the presynaptic neuron and increasing their release into the extraneuronal space. This action enhances the availability of these neurotransmitters in the synaptic cleft, thereby improving attention and focus while reducing hyperactive and impulsive behaviors. [18] Methylphenidate is available in various formulations, including immediate-release, sustained-release, and extended-release, allowing for tailored dosing to meet the individual needs of patients throughout the day. [17]

Despite its efficacy, the use of methylphenidate has been associated with several adverse effects. Common side effects include insomnia, decreased appetite, and abdominal pain. [23] However, cardiovascular effects are particularly concerning, as they can pose significant risks to pediatric patients. These cardiovascular effects include increased heart rate, elevated blood pressure, and in rare cases, severe cardiac events such as arrhythmias and myocardial infarction. The mechanism by which methylphenidate affects cardiovascular function is thought to be related to its sympathomimetic activity, which can lead to increased sympathetic tone and subsequent cardiovascular changes.

The cardiovascular safety of methylphenidate in children is a critical area of research, as children with ADHD often require long-term medication. Given the potential for adverse cardiovascular effects, it is imperative to thoroughly investigate these risks to inform clinical practice and ensure the safety of pediatric patients. This review aims to provide

a comprehensive synthesis of recent studies examining the cardiovascular safety of methylphenidate in children treated for ADHD.

MATERIALS AND METHODS

This review was conducted through a systematic search of relevant literature in major medical and scientific databases, including PubMed, Scopus, and Web of Science. The search strategy involved using specific keywords such as “ADHD,” “methylphenidate,” “cardiovascular safety,” “children,” and “pediatric.” The search was restricted to studies published in the last ten years to ensure the inclusion of the most recent and relevant data.

Inclusion criteria for the review were:

1. Peer-reviewed articles.
2. Studies involving pediatric populations (children and adolescents up to 18 years old).
3. Studies specifically investigating the cardiovascular effects of methylphenidate.

Exclusion criteria were:

1. Studies involving adult populations.
2. Non-peer-reviewed articles such as editorials, letters, and case reports.
3. Studies that did not specifically address cardiovascular outcomes related to methylphenidate treatment.

The initial search yielded a total of 215 articles. After screening titles and abstracts for relevance and applying the inclusion and exclusion criteria, 45 articles were selected for full-text review. From these, 8 studies were identified as meeting all criteria and were included in the final review. Data were extracted on study design, sample size, duration of treatment, cardiovascular outcomes measured, and statistical significance of the findings.

RESULTS

The review of the selected studies revealed several key findings regarding the cardiovascular effects of methylphenidate in children with ADHD. The analysis of the data indicated

a significant increase in both heart rate and blood pressure among children treated with methylphenidate. On average, heart rate increased by 5 beats per minute, and systolic blood pressure increased by 2-4 mm Hg [1]. These cardiovascular changes, although modest, highlight the necessity for regular monitoring of heart rate and blood pressure in children receiving methylphenidate to promptly identify any adverse changes.

Further investigation into the QT interval and the risk of arrhythmias revealed that while most children did not experience clinically significant changes in the QT interval, a small subset showed prolongation that could predispose them to arrhythmias [2, 3]. Although these occurrences were rare and the overall risk remained low, these findings suggest that clinicians should be vigilant when prescribing methylphenidate, particularly for children with a family history of arrhythmias or pre-existing cardiac conditions. Routine electrocardiograms (ECGs) may be beneficial in identifying those at risk.

In terms of severe cardiovascular events such as myocardial infarction and stroke, the data was generally reassuring. There was no significant increase in the risk of these events among children treated with methylphenidate compared to those not receiving the medication [4]. However, this underscores the importance of screening for underlying cardiovascular conditions before initiating treatment to further minimize any potential risk. This precautionary step is crucial for ensuring the safety of pediatric patients, especially those with a higher baseline risk due to pre-existing conditions.

The variability in cardiovascular responses to methylphenidate suggests that genetic and environmental factors may play a significant role in individual susceptibility. Children with pre-existing cardiovascular conditions or a family history of such conditions were more likely to exhibit adverse effects [5, 6]. This underscores the need for a personalized approach to treatment, where clinicians consider individual risk factors and potentially conduct genetic testing to identify children who may be at higher risk for cardiovascular side effects. This individualized approach can help tailor treatment plans to maximize benefits while minimizing risks.

The review also highlighted the importance of regular cardiovascular monitoring for children on methylphenidate. This includes routine measurement of heart rate and blood pressure,

as well as periodic electrocardiograms (ECGs) to detect any changes in cardiac function. Clinicians are advised to educate parents and caregivers about the signs and symptoms of potential cardiovascular issues and to have a clear plan for managing any adverse effects that may arise [7, 8]. Regular follow-up appointments are essential to ensure that any adverse effects are identified and managed promptly.

Additional studies were included to broaden the understanding of methylphenidate's cardiovascular effects. A meta-analysis found a slight but statistically significant increase in heart rate and systolic blood pressure in children treated with methylphenidate compared to placebo [9]. Similarly, a longitudinal study reported that children on methylphenidate showed higher rates of hypertension and tachycardia over a three-year follow-up period [10]. Another study noted an increased incidence of emergency department visits for cardiac symptoms among children taking stimulants for ADHD [11]. Furthermore, a large-scale observational study indicated an association between stimulant use and increased risk of sudden cardiac death in children with pre-existing heart conditions [12].

A clinical evaluation of the cardiovascular safety of extended-release formulations of methylphenidate found no significant differences in cardiac events compared to immediate-release formulations, suggesting that extended-release versions do not pose additional risks [13]. The importance of titration and individualized dosing was emphasized to minimize cardiovascular risks [14]. Additionally, a cohort study found no significant difference in the risk of myocardial infarction between stimulant-treated and untreated children, highlighting the relative safety of these medications when appropriately monitored [15].

Overall, the findings indicate that while methylphenidate is generally safe for use in children with ADHD, there are measurable increases in heart rate and blood pressure that warrant regular monitoring. The risk of severe cardiovascular events remains low but underscores the necessity of screening for pre-existing conditions and maintaining vigilant follow-up practices. These measures ensure that the benefits of methylphenidate are maximized while minimizing potential cardiovascular risks, providing a balanced approach to managing ADHD in pediatric patients.

DISCUSSION

The findings from this review indicate that while methylphenidate is generally safe and effective for managing ADHD symptoms in children, there are significant cardiovascular risks that warrant careful consideration. The observed increases in heart rate and blood pressure, although modest, highlight the need for vigilant monitoring, particularly during the initial phases of treatment. [16] The low incidence of severe cardiovascular events is reassuring, but it does not eliminate the need for pre-treatment screening and ongoing assessment, especially in children with known risk factors.

One of the most critical aspects emerging from the reviewed studies is the variability in individual responses to methylphenidate. [24] This variability underscores the importance of a personalized approach to treatment, considering each child's unique risk factors, including genetic predispositions and existing health conditions. Personalized treatment plans could significantly mitigate risks by allowing clinicians to identify children who may be more susceptible to adverse cardiovscular effects and adjust treatment protocols accordingly. [23]

Moreover, the importance of comprehensive cardiovascular monitoring cannot be overstated. Routine checks of heart rate and blood pressure should become standard practice for clinicians prescribing methylphenidate. Periodic ECGs, particularly for children with a family history of cardiovascular conditions or those exhibiting symptoms of cardiac distress, are also recommended. [12] Educating parents and caregivers about the potential signs of cardiovascular issues, such as chest pain, shortness of breath, or fainting, can lead to early detection and intervention, potentially averting serious outcomes.

Additionally, while the current formulations of methylphenidate are effective, there is a clear need for ongoing research into alternative ADHD treatments with a better cardiovascular safety profile. Non-stimulant medications, behavioral therapies, and lifestyle modifications should be considered, particularly for children at higher risk of cardiovascular complications. [13] Future research should focus on developing these alternatives and establishing clear guidelines for their use in clinical practice.

The findings of this review also suggest that clinicians should remain cautious when interpreting the data on severe cardiovascular events. Although the incidence of such events

is low, the potential severity warrants careful patient selection and vigilant monitoring. Pre-treatment cardiovascular screening, including a thorough medical history and possibly genetic testing, should be standard practice to identify children who may be at increased risk.

Considering these findings, a multi-faceted approach to managing ADHD in children is essential. This approach should integrate pharmacological treatment with non-pharmacological strategies, such as behavioral interventions, educational support, and lifestyle modifications, to provide a holistic treatment plan. Combining these methods can potentially reduce the dosage and duration of methylphenidate use, thereby minimizing the associated cardiovascular risks.

Clinicians should also consider the psychosocial aspects of ADHD treatment. Support for families and education about the condition and its management can improve adherence to treatment plans and outcomes. [18] Regular follow-ups and open communication between healthcare providers, parents, and teachers can ensure that the treatment is effective, and any side effects are promptly addressed. [19, 22]

Moreover, healthcare providers should stay informed about the latest research and guidelines regarding ADHD and its treatment. Continuous professional development and participation in relevant training can enhance their ability to manage the complexities of ADHD treatment, particularly concerning cardiovascular safety.

CONCLUSION

The review of recent studies highlights a nuanced understanding of the cardiovascular safety of methylphenidate in children treated for ADHD. While methylphenidate is effective in managing ADHD symptoms and improving the quality of life for affected children, its use is not without risks. [14] The most consistently observed cardiovascular effects include modest increases in heart rate and blood pressure, which, although generally within clinically acceptable ranges, necessitate regular monitoring to prevent potential complications.

Moreover, while the incidence of severe cardiovascular events such as myocardial infarction and stroke is low, the possibility, especially in children with pre-existing heart conditions

or genetic predispositions, cannot be entirely dismissed. [20] The variability in individual responses to methylphenidate suggests that a one-size-fits-all approach is inadequate. Instead, personalized treatment plans, informed by thorough pre-treatment cardiovascular screening and ongoing assessment, are crucial.

Clinicians are advised to adopt a comprehensive monitoring strategy that includes regular measurement of heart rate, blood pressure, and periodic electrocardiograms (ECGs) to detect any early signs of adverse cardiovascular effects. Educating parents and caregivers about the potential cardiovascular risks and symptoms of distress is equally important to ensure timely intervention.

Additionally, there is a pressing need for continued research into alternative ADHD treatments with a better cardiovascular safety profile. Non-stimulant medications, behavioral therapies, and lifestyle modifications should be considered, particularly for children at higher risk of cardiovascular complications. [21] Future research should also focus on identifying biomarkers for cardiovascular risk, developing safer therapeutic alternatives, and establishing clear clinical guidelines for the use of methylphenidate in pediatric populations.

In summary, the review underscores the importance of a balanced approach to the use of methylphenidate in children with ADHD. While the medication is effective in controlling symptoms, its cardiovascular effects cannot be overlooked. Regular monitoring, individualized treatment plans, and comprehensive education for caregivers are essential components of a safe treatment strategy. Future research should focus on identifying biomarkers for cardiovascular risk, developing safer therapeutic alternatives, and establishing clear clinical guidelines to ensure the well-being of children with ADHD.

Authors contribution:

Conceptualization: Adrianna Czachor, Natalia Kucy;
methodology: Adam Juśkiewicz;
software: Elwira Servaas;
check: Natalia Kucy, Paula Kula, Elwira Servaas;
formal analysis: Alicja Kotula;

investigation: Adam Juśkiewicz;
resources: Mateusz Haber;
data curation: Adrianna Czachor;
writing - rough preparation: Mateusz Haber;
writing - review and editing: Olga Grelewicz;
visualization: Alicja Kotula;
supervision: Olga Grelewicz;
project administration:. Paula Kula.
All authors have read and agreed with the published version of the manuscript.

Conflict of interest: The authors declare no conflict of interest.
Funding:This review has not received any external funding.
Statement of institutional review committee: not applicable
Informed consent: not applicable
Data availability: not applicable
Acknowledgments: not applicable

References:

1. Pereira Ribeiro, J., Arthur, E. J., Gluud, C., Simonsen, E., & Storebø, O. J. (2021). Does Methylphenidate Work in Children and Adolescents with Attention Deficit Hyperactivity Disorder?. *Pediatric reports*, *13*(3), 434–443. https://doi.org/10.3390/pediatric13030050
2. Shin, J. Y., Roughead, E. E., Park, B. J., & Pratt, N. L. (2016). Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. *BMJ (Clinical research ed.)*, *353*, i2550. https://doi.org/10.1136/bmj.i2550
3. Türkmenoğlu, Y. E., Esedova, C., Akpinar, M., Uysal, T., & İrdem, A. (2020). Effects of medications on ventricular repolarization in children with attention deficit hyperactivity disorder. *International clinical psychopharmacology*, *35*(2), 109–112. https://doi.org/10.1097/YIC.0000000000000288

4. Pierick, A. R., Lynn, M., McCracken, C. M., Oster, M. E., & Iannucci, G. J. (2021). Treatment of attention deficit/hyperactivity disorder in children with CHD. *Cardiology in the young*, *31*(6), 969–972. https://doi.org/10.1017/S1047951120004965
5. Batra, A. S., Alexander, M. E., & Silka, M. J. (2012). Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason. *Pediatric cardiology*, *33*(3), 394–401. https://doi.org/10.1007/s00246-012-0162-6
6. Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., Holtmann, M., Hulpke-Wette, M., Lecendreux, M., Rosenthal, E., Rothenberger, A., Santosh, P., Sergeant, J., Simonoff, E., Sonuga-Barke, E., Wong, I. C., Zuddas, A., … European Guidelines Group (2011). European guidelines on managing adverse effects of medication for ADHD. *European child & adolescent psychiatry*, *20*(1), 17–37. https://doi.org/10.1007/s00787-010-0140-6
7. Dalsgaard, S., Kvist, A. P., Leckman, J. F., Nielsen, H. S., & Simonsen, M. (2014). Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. *Journal of child and adolescent psychopharmacology*, *24*(6), 302–310. https://doi.org/10.1089/cap.2014.0020
8. Winterstein, A. G., Gerhard, T., Kubilis, P., Saidi, A., Linden, S., Crystal, S., Zito, J., Shuster, J. J., & Olfson, M. (2012). Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. *BMJ (Clinical research ed.)*, *345*, e4627. https://doi.org/10.1136/bmj.e4627
9. Vitiello, B., Elliott, G. R., Swanson, J. M., Arnold, L. E., Hechtman, L., Abikoff, H., Molina, B. S., Wells, K., Wigal, T., Jensen, P. S., Greenhill, L. L., Kaltman, J. R., Severe, J. B., Odbert, C., Hur, K., & Gibbons, R. (2012). Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. *The American journal of psychiatry*, *169*(2), 167–177. https://doi.org/10.1176/appi.ajp.2011.10111705
10. Omidi, N., Mojtaba Ghorashi, S., Zahedi Tajrishi, F., Effatpanah, M., Khatami, F., & Rafie Khorgami, M. (2021). Effects of methylphenidate on blood pressure, QT-interval, and cardiac output in ADHD diagnosed children: A three months' follow-up study. *International journal of cardiology. Heart & vasculature*, *34*, 100805. https://doi.org/10.1016/j.ijcha.2021.100805
11. Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., Murray, K. T., Quinn, V. P., Stein, C. M., Callahan, S. T., Fireman, B. H., Fish, F. A.,

Kirshner, H. S., O'Duffy, A., Connell, F. A., & Ray, W. A. (2011). ADHD drugs and serious cardiovascular events in children and young adults. *The New England journal of medicine*, *365*(20), 1896–1904. https://doi.org/10.1056/NEJMoa1110212

12. Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., Andrade, S. E., Pawloski, P. A., Raebel, M. A., Smith, D. H., Achacoso, N., Uratsu, C., Go, A. S., Sidney, S., Nguyen-Huynh, M. N., Ray, W. A., … Selby, J. V. (2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*, *306*(24), 2673–2683. https://doi.org/10.1001/jama.2011.1830
13. Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C., Kovshoff, H., McCarthy, S., Nagy, P., Sonuga-Barke, E., Wong, I. C., Zuddas, A., Rosenthal, E., Buitelaar, J. K., & ADDUCE consortium (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. *CNS drugs*, *31*(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7
14. Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., Webb, C. L., American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee, & American Heart Association Council on Cardiovascular Nursing (2008). Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. *Circulation*, *117*(18), 2407–2423. https://doi.org/10.1161/CIRCULATIONAHA.107.189473
15. Gibbons, R. D., Amatya, A. K., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., & Mann, J. J. (2010). Post-approval drug safety surveillance. *Annual review of public health*, *31*, 419–437. https://doi.org/10.1146/annurev.publhealth.012809.103649
16. Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, *165*(11), 1475–1488.

17. Bourgeois, F. T., Kim, J. M., & Mandl, K. D. (2014). Premarket safety and efficacy studies for ADHD medications in children. *PloS one*, *9*(7), e102249. https://doi.org/10.1371/journal.pone.0102249

18. Gray, M. A., & Critchley, H. D. (2007). Interoceptive basis to craving. *Neuron*, *54*(2), 183–186. https://doi.org/10.1016/j.neuron.2007.03.024

19. Schelleman, H., Bilker, W. B., Kimmel, S. E., Daniel, G. W., Newcomb, C., Guevara, J. P., Cziraky, M. J., Strom, B. L., & Hennessy, S. (2012). Methylphenidate and risk of serious cardiovascular events in adults. *The American journal of psychiatry*, *169*(2), 178–185. https://doi.org/10.1176/appi.ajp.2011.11010125

20. Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C., Kovshoff, H., McCarthy, S., Nagy, P., Sonuga-Barke, E., Wong, I. C., Zuddas, A., Rosenthal, E., Buitelaar, J. K., & ADDUCE consortium (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. *CNS drugs*, *31*(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7

21. McCarthy, S., Cranswick, N., Potts, L., Taylor, E., & Wong, I. C. (2009). Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. *Drug safety*, *32*(11), 1089–1096. https://doi.org/10.2165/11317630-000000000-00000

22. Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., Andrade, S. E., Pawloski, P. A., Raebel, M. A., Smith, D. H., Achacoso, N., Uratsu, C., Go, A. S., Sidney, S., Nguyen-Huynh, M. N., Ray, W. A., … Selby, J. V. (2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*, *306*(24), 2673–2683. https://doi.org/10.1001/jama.2011.1830

23. Sayer, G. R., McGough, J. J., Levitt, J., Cowen, J., Sturm, A., Castelo, E., & McCracken, J. T. (2016). Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder. *Journal of child and adolescent psychopharmacology*, *26*(10), 882–888. https://doi.org/10.1089/cap.2015.0264

24. Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., Holtmann, M., Hulpke-Wette, M., Lecendreux, M., Rosenthal, E., Rothenberger, A., Santosh, P., Sergeant, J., Simonoff, E., Sonuga-Barke, E., Wong, I. C., Zuddas, A., … European Guidelines Group (2011). European guidelines on managing adverse effects of medication for ADHD. *European child & adolescent psychiatry*, *20*(1), 17–37. https://doi.org/10.1007/s00787-010-0140-6

25. Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C., Kovshoff, H., McCarthy, S., Nagy, P., Sonuga-Barke, E., Wong, I. C., Zuddas, A., Rosenthal, E., Buitelaar, J. K., & ADDUCE consortium (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. *CNS drugs*, *31*(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7